{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:44:15Z","timestamp":1790790255847,"version":"4.1.0"},"reference-count":90,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,12,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Systemic amyloidosis is caused by misfolding and extracellular deposition of circulating proteins as amyloid fibrils, resulting in the dysfunction of vital organs. The most common systemic amyloidosis, light-chain (AL) amyloidosis, is caused by misfolded light chains produced by a small, dangerous B-cell clone. The process of amyloid formation, organ targeting, and damage is multifaceted and, after disease initiation, the complexity of the downstream pathogenic cascade increases, rendering its control a challenge. Because of the progressive nature of the disease, early diagnosis to prevent end-stage organ damage is vital. Improving awareness and systematic use of biomarkers of organ damage in screening populations at risk may improve the still unsatisfactory diagnostic process. Amyloid imaging is now emerging as an important companion of biomarkers in formulating the diagnosis and prognosis and monitoring the effects of therapy. An accurate diagnosis is the basis for appropriate therapy that is risk-adapted and response-tailored. Effective treatments targeting the clone and rapidly and profoundly reducing the amyloid light chains have produced marked improvements in overall survival, making AL amyloidosis the most successful model of all amyloidoses. New therapies targeting the amyloid deposits are now under development, together with novel agents modulating light chain aggregation and proteotoxicity. The future of AL amyloidosis treatment is combination therapy and will require an innovative collaborative model for a rapid translation from bench to bedside with the ultimate aim of achieving a cure for this complex disease.<\/jats:p>","DOI":"10.1182\/asheducation-2017.1.1","type":"journal-article","created":{"date-parts":[[2019,4,16]],"date-time":"2019-04-16T18:13:11Z","timestamp":1555438391000},"page":"1-12","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":173,"title":["AL amyloidosis: from molecular mechanisms to targeted therapies"],"prefix":"10.1182","volume":"2017","author":[{"given":"Giampaolo","family":"Merlini","sequence":"first","affiliation":[{"name":"Amyloidosis Research and Treatment Center, Foundation Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Department of Molecular Medicine, University of Pavia, Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"6","key":"2019111703043337700_B1","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1056\/NEJMra023144","article-title":"Molecular mechanisms of amyloidosis","volume":"349","author":"Merlini","year":"2003","journal-title":"N Engl J Med"},{"issue":"7628","key":"2019111703043337700_B2","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/nature20416","article-title":"The activities of amyloids from a structural perspective","volume":"539","author":"Riek","year":"2016","journal-title":"Nature"},{"key":"2019111703043337700_B3","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1146\/annurev-biochem-061516-045115","article-title":"Protein misfolding, amyloid formation, and human disease: a summary of progress over the last decade","volume":"86","author":"Chiti","year":"2017","journal-title":"Annu Rev Biochem"},{"issue":"14","key":"2019111703043337700_B4","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1200\/JCO.2010.32.2271","article-title":"Amyloidosis: pathogenesis and new therapeutic options","volume":"29","author":"Merlini","year":"2011","journal-title":"J Clin Oncol"},{"key":"2019111703043337700_B5","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1146\/annurev-biochem-072711-163904","article-title":"Extracellular chaperones and proteostasis","volume":"82","author":"Wyatt","year":"2013","journal-title":"Annu Rev Biochem"},{"key":"2019111703043337700_B6","doi-asserted-by":"crossref","first-page":"29096","DOI":"10.1038\/srep29096","article-title":"In situ characterization of protein aggregates in human tissues affected by light chain amyloidosis: a FTIR microspectroscopy study","volume":"6","author":"Ami","year":"2016","journal-title":"Sci Rep"},{"key":"2019111703043337700_B7","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1146\/annurev-biochem-072611-130030","article-title":"Systemic amyloidoses","volume":"82","author":"Blancas-Mej\u00eda","year":"2013","journal-title":"Annu Rev Biochem"},{"issue":"21","key":"2019111703043337700_B8","doi-asserted-by":"crossref","first-page":"4280","DOI":"10.1016\/j.jmb.2016.08.021","article-title":"The kinetic stability of a full-length antibody light chain dimer determines whether endoproteolysis can release amyloidogenic variable domains","volume":"428","author":"Morgan","year":"2016","journal-title":"J Mol Biol"},{"key":"2019111703043337700_B9","doi-asserted-by":"crossref","first-page":"e10935","DOI":"10.7554\/eLife.10935","article-title":"Inhibition by small-molecule ligands of formation of amyloid fibrils of an immunoglobulin light chain variable domain","volume":"4","author":"Brumshtein","year":"2015","journal-title":"eLife"},{"key":"2019111703043337700_B10","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev.med.57.121304.131243","article-title":"Amyloidosis","volume":"57","author":"Pepys","year":"2006","journal-title":"Annu Rev Med"},{"issue":"6","key":"2019111703043337700_B11","doi-asserted-by":"crossref","first-page":"595","DOI":"10.15252\/emmm.201606210","article-title":"The amyloid hypothesis of Alzheimer\u2019s disease at 25 years","volume":"8","author":"Selkoe","year":"2016","journal-title":"EMBO Mol Med"},{"issue":"38","key":"2019111703043337700_B12","doi-asserted-by":"crossref","first-page":"19813","DOI":"10.1074\/jbc.M116.736736","article-title":"Cell damage in light chain amyloidosis: fibril internalization, toxicity and cell-mediated seeding","volume":"291","author":"Marin-Argany","year":"2016","journal-title":"J Biol Chem"},{"issue":"1","key":"2019111703043337700_B13","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1182\/blood-2011-05-355784","article-title":"The repertoire of \u03bb light chains causing predominant amyloid heart involvement and identification of a preferentially involved germline gene, IGLV1-44","volume":"119","author":"Perfetti","year":"2012","journal-title":"Blood"},{"issue":"3","key":"2019111703043337700_B14","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1182\/blood-2016-10-743997","article-title":"Clarifying immunoglobulin gene usage in systemic and localized immunoglobulin light-chain amyloidosis by mass spectrometry","volume":"129","author":"Kourelis","year":"2017","journal-title":"Blood"},{"issue":"26","key":"2019111703043337700_B15","doi-asserted-by":"crossref","first-page":"5124","DOI":"10.1182\/blood-2013-01-453001","article-title":"Systemic light chain amyloidosis: an update for treating physicians","volume":"121","author":"Merlini","year":"2013","journal-title":"Blood"},{"issue":"23","key":"2019111703043337700_B16","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1182\/blood-2013-10-525634","article-title":"A Caenorhabditis elegans-based assay recognizes immunoglobulin light chains causing heart amyloidosis","volume":"123","author":"Diomede","year":"2014","journal-title":"Blood"},{"issue":"1","key":"2019111703043337700_B17","doi-asserted-by":"crossref","first-page":"H95","DOI":"10.1152\/ajpheart.00186.2013","article-title":"Human amyloidogenic light chain proteins result in cardiac dysfunction, cell death, and early mortality in zebrafish","volume":"305","author":"Mishra","year":"2013","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2019111703043337700_B18","article-title":"Cardiac light chain amyloidosis: the role of metal ions in oxidative stress and mitochondrial damage [published online ahead of print 3 March 2017]","author":"Diomede","journal-title":"Antioxid Redox Signal"},{"issue":"11","key":"2019111703043337700_B19","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.15252\/emmm.201404190","article-title":"Lysosomal dysfunction and impaired autophagy underlie the pathogenesis of amyloidogenic light chain-mediated cardiotoxicity","volume":"6","author":"Guan","year":"2014","journal-title":"EMBO Mol Med"},{"issue":"9","key":"2019111703043337700_B20","doi-asserted-by":"crossref","first-page":"4188","DOI":"10.1073\/pnas.0912263107","article-title":"Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a non-canonical p38alpha MAPK pathway","volume":"107","author":"Shi","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"issue":"11","key":"2019111703043337700_B21","doi-asserted-by":"crossref","first-page":"4614","DOI":"10.1096\/fj.15-272179","article-title":"Novel mitochondrial protein interactors of immunoglobulin light chains causing heart amyloidosis","volume":"29","author":"Lavatelli","year":"2015","journal-title":"FASEB J"},{"issue":"10","key":"2019111703043337700_B22","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1038\/leu.2016.191","article-title":"Rationale, application and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosis","volume":"30","author":"Merlini","year":"2016","journal-title":"Leukemia"},{"issue":"19","key":"2019111703043337700_B23","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1161\/01.CIR.0000068314.02595.B2","article-title":"Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis","volume":"107","author":"Palladini","year":"2003","journal-title":"Circulation"},{"issue":"10","key":"2019111703043337700_B24","doi-asserted-by":"crossref","first-page":"3854","DOI":"10.1182\/blood-2005-11-4385","article-title":"Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL","volume":"107","author":"Palladini","year":"2006","journal-title":"Blood"},{"issue":"13","key":"2019111703043337700_B25","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1161\/CIRCULATIONAHA.108.843334","article-title":"Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types","volume":"120","author":"Rapezzi","year":"2009","journal-title":"Circulation"},{"issue":"8","key":"2019111703043337700_B26","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1182\/blood-2006-03-001164","article-title":"Dangerous small B-cell clones","volume":"108","author":"Merlini","year":"2006","journal-title":"Blood"},{"issue":"34","key":"2019111703043337700_B27","doi-asserted-by":"crossref","first-page":"4319","DOI":"10.1200\/JCO.2013.50.8499","article-title":"Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis","volume":"31","author":"Kourelis","year":"2013","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019111703043337700_B28","doi-asserted-by":"crossref","first-page":"e537","DOI":"10.1038\/bcj.2017.19","article-title":"Mutational landscape reflects the biological continuum of plasma cell dyscrasias","volume":"7","author":"Rossi","year":"2017","journal-title":"Blood Cancer J"},{"issue":"12","key":"2019111703043337700_B29","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1200\/JCO.2014.57.4947","article-title":"Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens","volume":"33","author":"Bochtler","year":"2015","journal-title":"J Clin Oncol"},{"issue":"7","key":"2019111703043337700_B30","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1038\/leu.2016.369","article-title":"Interphase fluorescence in situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment category","volume":"31","author":"Muchtar","year":"2017","journal-title":"Leukemia"},{"issue":"15","key":"2019111703043337700_B31","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1182\/blood-2016-08-730978","article-title":"The amyloidogenic light chain is a stressor that sensitizes plasma cells to proteasome inhibitor toxicity","volume":"129","author":"Oliva","year":"2017","journal-title":"Blood"},{"issue":"8600","key":"2019111703043337700_B32","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S0140-6736(88)92235-0","article-title":"Diagnostic radionuclide imaging of amyloid: biological targeting by circulating human serum amyloid P component","volume":"1","author":"Hawkins","year":"1988","journal-title":"Lancet"},{"issue":"12","key":"2019111703043337700_B33","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1007\/BF01791147","article-title":"Cardiac and pleuropulmonary AL amyloid imaging with technetium-99m labelled aprotinin","volume":"22","author":"Aprile","year":"1995","journal-title":"Eur J Nucl Med"},{"issue":"24","key":"2019111703043337700_B34","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"issue":"2","key":"2019111703043337700_B35","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s10741-014-9470-7","article-title":"Cardiovascular magnetic resonance for amyloidosis","volume":"20","author":"Fontana","year":"2015","journal-title":"Heart Fail Rev"},{"issue":"7","key":"2019111703043337700_B36","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1182\/blood.V79.7.1817.1817","article-title":"Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989","volume":"79","author":"Kyle","year":"1992","journal-title":"Blood"},{"issue":"10","key":"2019111703043337700_B37","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.3324\/haematol.2013.094482","article-title":"Light chain amyloidosis: the heart of the problem","volume":"98","author":"Merlini","year":"2013","journal-title":"Haematologica"},{"issue":"1","key":"2019111703043337700_B38","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jacc.2016.04.035","article-title":"Cardiac amyloid load: a prognostic and predictive biomarker in patients with light-chain amyloidosis","volume":"68","author":"Kristen","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"2019111703043337700_B39","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/clinchem\/47.4.673","article-title":"Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine","volume":"47","author":"Bradwell","year":"2001","journal-title":"Clin Chem"},{"issue":"18","key":"2019111703043337700_B40","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.1200\/JCO.2004.03.029","article-title":"Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis","volume":"22","author":"Dispenzieri","year":"2004","journal-title":"J Clin Oncol"},{"issue":"36","key":"2019111703043337700_B41","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1200\/JCO.2011.37.7614","article-title":"New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes","volume":"30","author":"Palladini","year":"2012","journal-title":"J Clin Oncol"},{"issue":"15","key":"2019111703043337700_B42","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1182\/blood-2014-04-570010","article-title":"A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis","volume":"124","author":"Palladini","year":"2014","journal-title":"Blood"},{"key":"2019111703043337700_B43","doi-asserted-by":"crossref","DOI":"10.1182\/asheducation.V2012.1.595.3798563","article-title":"Differential diagnosis of monoclonal gammopathy of undetermined significance","author":"Merlini","year":"2012"},{"issue":"14","key":"2019111703043337700_B44","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1182\/blood-2014-11-609883","article-title":"A practical approach to the diagnosis of systemic amyloidoses","volume":"125","author":"Fern\u00e1ndez de Larrea","year":"2015","journal-title":"Blood"},{"issue":"2","key":"2019111703043337700_B45","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1182\/blood-2016-01-629790","article-title":"What is new in diagnosis and management of light chain amyloidosis?","volume":"128","author":"Palladini","year":"2016","journal-title":"Blood"},{"issue":"3","key":"2019111703043337700_B46","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1373\/clinchem.2008.117143","article-title":"Identification of amyloidogenic light chains requires the combination of serum-free light chain assay with immunofixation of serum and urine","volume":"55","author":"Palladini","year":"2009","journal-title":"Clin Chem"},{"issue":"9","key":"2019111703043337700_B47","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1200\/JCO.2011.38.5724","article-title":"Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements","volume":"30","author":"Kumar","year":"2012","journal-title":"J Clin Oncol"},{"issue":"17","key":"2019111703043337700_B48","doi-asserted-by":"crossref","first-page":"3420","DOI":"10.1182\/blood-2012-12-473066","article-title":"A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis","volume":"121","author":"Wechalekar","year":"2013","journal-title":"Blood"},{"issue":"5","key":"2019111703043337700_B49","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/ajh.23141","article-title":"Best use of cardiac biomarkers in patients with AL amyloidosis and renal failure","volume":"87","author":"Palladini","year":"2012","journal-title":"Am J Hematol"},{"issue":"18","key":"2019111703043337700_B50","doi-asserted-by":"crossref","first-page":"3426","DOI":"10.1182\/blood-2010-05-286567","article-title":"The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis","volume":"116","author":"Palladini","year":"2010","journal-title":"Blood"},{"issue":"12","key":"2019111703043337700_B51","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.jacc.2012.04.043","article-title":"Longitudinal left ventricular function for prediction of survival in systemic light-chain amyloidosis: incremental value compared with clinical and biochemical markers","volume":"60","author":"Buss","year":"2012","journal-title":"J Am Coll Cardiol"},{"issue":"22","key":"2019111703043337700_B52","doi-asserted-by":"crossref","first-page":"3261","DOI":"10.1182\/blood.V128.22.3261.3261","article-title":"Persistence of minimal residual disease by multiparameter flow cytometry can hinder recovery of organ damage in patients with AL amyloidosis otherwise in complete response [abstract]","volume":"128","author":"Palladini","year":"2016","journal-title":"Blood"},{"issue":"(","key":"2019111703043337700_B53","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1182\/blood-2017-02-767467","article-title":"Patients with light chain amyloidosis and low free light chain burden have distinct clinical features and outcome","volume":"130","author":"Milani","year":"2017","journal-title":"Blood"},{"key":"2019111703043337700_B54","article-title":"AL amyloidosis patients with low amyloidogenic free light chain levels at first diagnosis have an excellent prognosis [published online ahead of print 26 May 2017]","author":"Dittrich","journal-title":"Blood"},{"issue":"15","key":"2019111703043337700_B55","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1182\/blood-2016-11-751628","article-title":"Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death","volume":"129","author":"Muchtar","year":"2017","journal-title":"Blood"},{"issue":"22","key":"2019111703043337700_B56","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.646.646","article-title":"A randomized phase III trial of melphalan and dexamethasone (MDex) versus bortezomib, melphalan and dexamethasone (BMDex) for untreated patients with AL amyloidosis [abstract]","volume":"128","author":"Kastritis","year":"2016","journal-title":"Blood"},{"issue":"7","key":"2019111703043337700_B57","doi-asserted-by":"crossref","first-page":"2801","DOI":"10.1182\/blood.V88.7.2801.bloodjournal8872801","article-title":"Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: one-year follow-up in five patients","volume":"88","author":"Comenzo","year":"1996","journal-title":"Blood"},{"issue":"32","key":"2019111703043337700_B58","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1200\/JCO.2015.62.4015","article-title":"Improved outcomes after autologous hematopoietic cell transplantation for light chain amyloidosis: a Center for International Blood and Marrow Transplant Research Study","volume":"33","author":"D\u2019Souza","year":"2015","journal-title":"J Clin Oncol"},{"issue":"8","key":"2019111703043337700_B59","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1038\/bmt.2017.68","article-title":"Revisiting conditioning dose in newly diagnosed light chain amyloidosis undergoing frontline autologous stem cell transplant: impact on response and survival","volume":"52","author":"Tandon","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"2019111703043337700_B60","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1056\/NEJMoa070484","article-title":"High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis","volume":"357","author":"Jaccard","year":"2007","journal-title":"N Engl J Med"},{"issue":"20","key":"2019111703043337700_B61","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1182\/blood-2015-08-662726","article-title":"Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem cell transplantation: 20-year experience","volume":"126","author":"Sanchorawala","year":"2015","journal-title":"Blood"},{"issue":"8","key":"2019111703043337700_B62","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.1182\/blood-2003-08-2788","article-title":"Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation","volume":"103","author":"Palladini","year":"2004","journal-title":"Blood"},{"issue":"4","key":"2019111703043337700_B63","doi-asserted-by":"crossref","first-page":"743","DOI":"10.3324\/haematol.2013.095463","article-title":"Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach","volume":"99","author":"Palladini","year":"2014","journal-title":"Haematologica"},{"issue":"4","key":"2019111703043337700_B64","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1182\/blood-2011-02-334227","article-title":"Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1\/2 study","volume":"118","author":"Reece","year":"2011","journal-title":"Blood"},{"issue":"19","key":"2019111703043337700_B65","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1182\/blood-2011-11-390930","article-title":"Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis","volume":"119","author":"Mikhael","year":"2012","journal-title":"Blood"},{"issue":"12","key":"2019111703043337700_B66","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1038\/leu.2014.227","article-title":"Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case-control study on 174 patients","volume":"28","author":"Palladini","year":"2014","journal-title":"Leukemia"},{"issue":"12","key":"2019111703043337700_B67","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1038\/leu.2014.218","article-title":"A matched comparison of cyclophosphamide, bortezomib and dexamethasone (CVD) versus risk-adapted cyclophosphamide, thalidomide and dexamethasone (CTD) in AL amyloidosis","volume":"28","author":"Venner","year":"2014","journal-title":"Leukemia"},{"issue":"5","key":"2019111703043337700_B68","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1182\/blood-2015-01-620302","article-title":"A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis","volume":"126","author":"Palladini","year":"2015","journal-title":"Blood"},{"issue":"23","key":"2019111703043337700_B69","doi-asserted-by":"crossref","first-page":"4777","DOI":"10.1182\/blood-2010-07-294405","article-title":"Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1\/2 dose-escalation study","volume":"116","author":"Moreau","year":"2010","journal-title":"Blood"},{"key":"2019111703043337700_B70","first-page":"1424","author":"Hegenbart","year":"2017"},{"key":"2019111703043337700_B71","author":"Tandon","year":"2017"},{"issue":"1","key":"2019111703043337700_B72","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s00277-011-1244-x","article-title":"Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib, and thalidomide","volume":"91","author":"Palladini","year":"2012","journal-title":"Ann Hematol"},{"issue":"23","key":"2019111703043337700_B73","doi-asserted-by":"crossref","first-page":"5397","DOI":"10.1182\/blood-2012-02-413161","article-title":"Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis","volume":"119","author":"Dispenzieri","year":"2012","journal-title":"Blood"},{"issue":"15","key":"2019111703043337700_B74","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1182\/blood-2016-12-756528","article-title":"A phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis","volume":"129","author":"Palladini","year":"2017","journal-title":"Blood"},{"issue":"5","key":"2019111703043337700_B75","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1182\/blood-2017-03-771220","article-title":"A phase 1\/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis","volume":"130","author":"Sanchorawala","year":"2017","journal-title":"Blood"},{"issue":"22","key":"2019111703043337700_B76","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1182\/blood.V128.22.645.645","article-title":"Safety and efficacy of carfilzomib (CFZ) in previously-treated systemic light-chain (AL) amyloidosis [abstract]","volume":"128","author":"Cohen","year":"2016","journal-title":"Blood"},{"key":"2019111703043337700_B77","doi-asserted-by":"crossref","DOI":"10.1080\/13506129.2017.1292240","article-title":"Response to bendamustine is associated with a survival advantage in a heavily pretreated patients with AL amyloidosis","author":"Milani","year":"2017"},{"issue":"22","key":"2019111703043337700_B78","doi-asserted-by":"crossref","first-page":"5453","DOI":"10.1158\/1078-0432.CCR-16-0868","article-title":"Immune therapies in multiple myeloma","volume":"22","author":"Kumar","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"15","key":"2019111703043337700_B79","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1182\/blood-2016-06-722496","article-title":"First report of safety and efficacy of daratumumab in 2 cases of advanced immunoglobulin light chain amyloidosis","volume":"128","author":"Sher","year":"2016","journal-title":"Blood"},{"key":"2019111703043337700_B80","article-title":"Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis [published online ahead of print 14 June 2017]","author":"Kaufman","journal-title":"Blood"},{"issue":"22","key":"2019111703043337700_B81","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1182\/blood-2013-10-535187","article-title":"One siRNA pool targeting the \u03bb constant region stops \u03bb light-chain production and causes terminal endoplasmic reticulum stress","volume":"123","author":"Zhou","year":"2014","journal-title":"Blood"},{"issue":"7","key":"2019111703043337700_B82","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.1073\/pnas.92.7.2959","article-title":"Interaction of the anthracycline 4\u2032-iodo-4\u2032-deoxydoxorubicin with amyloid fibrils: inhibition of amyloidogenesis","volume":"92","author":"Merlini","year":"1995","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"2019111703043337700_B83","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1182\/blood.V86.3.855.855","article-title":"New drug therapy of amyloidoses: resorption of AL-type deposits with 4\u2032-iodo-4\u2032-deoxydoxorubicin","volume":"86","author":"Gianni","year":"1995","journal-title":"Blood"},{"issue":"1","key":"2019111703043337700_B84","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3109\/13506120209072441","article-title":"A multicenter phase II trial of 4'-iodo-4' deoxydoxorubicin (IDOX) in primary amyloidosis (AL)","volume":"9","author":"Gertz","year":"2002","journal-title":"Amyloid"},{"issue":"3","key":"2019111703043337700_B85","doi-asserted-by":"crossref","first-page":"e546","DOI":"10.1038\/bcj.2017.26","article-title":"Encouraging impact of doxycycline on early mortality in cardiac light chain (AL) amyloidosis","volume":"7","author":"Wechalekar","year":"2017","journal-title":"Blood Cancer J"},{"issue":"8","key":"2019111703043337700_B86","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s00392-010-0142-x","article-title":"Effects of the main green tea polyphenol epigallocatechin-3-gallate on cardiac involvement in patients with AL amyloidosis","volume":"99","author":"Mereles","year":"2010","journal-title":"Clin Res Cardiol"},{"issue":"22","key":"2019111703043337700_B87","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1182\/blood.V128.22.643.643","article-title":"Analysis of the phase 1a\/b study of chimeric fibril-reactive monoclonal antibody 11-1F4 in patients with AL amyloidosis [abstract]","volume":"128","author":"Edwards","year":"2016","journal-title":"Blood"},{"issue":"12","key":"2019111703043337700_B88","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1056\/NEJMoa1504942","article-title":"Therapeutic clearance of amyloid by antibodies to serum amyloid P component","volume":"373","author":"Richards","year":"2015","journal-title":"N Engl J Med"},{"issue":"10","key":"2019111703043337700_B89","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1200\/JCO.2015.63.6530","article-title":"First-in-human phase I\/II study of NEOD001 in patients with light chain amyloidosis and persistent organ dysfunction","volume":"34","author":"Gertz","year":"2016","journal-title":"J Clin Oncol"},{"issue":"6","key":"2019111703043337700_B90","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1111\/bjh.12973","article-title":"Lenalidomide and dexamethasone for systemic AL amyloidosis following prior treatment with thalidomide or bortezomib regimens","volume":"166","author":"Mahmood","year":"2014","journal-title":"Br J Haematol"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2017\/1\/1\/1249519\/hem00001.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2017\/1\/1\/1249519\/hem00001.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,6]],"date-time":"2020-12-06T10:12:56Z","timestamp":1607249576000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2017\/1\/1\/21042\/AL-amyloidosis-from-molecular-mechanisms-to"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,8]]},"references-count":90,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12,8]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2017.1.1","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.733668127.793549858","asserted-by":"object"}]},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,8]]}}}